[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10658
1. Barrett AJ, Le Blanc K: Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol; 2010 Aug;161(2):223-32
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy prospects for acute myeloid leukaemia.
  • While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse.
  • Strategies to prevent relapse involve consolidation chemotherapy, stem cell transplantation and immunotherapy.
  • Evidence for immunosurveillance of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction.
  • Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents.
  • Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure.
  • [MeSH-major] Immunotherapy / methods. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):483-4 [18938742.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4934-9 [18591543.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5192-7 [18854573.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2187-95 [19021063.001]
  • [Cites] Leukemia. 2009 Jan;23(1):53-8 [18830260.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Blood. 2009 Jan 22;113(4):875-82 [18922853.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1037-45 [19155305.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2245-55 [18988867.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2312-23 [19074734.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1761-70 [19273160.001]
  • [Cites] Leukemia. 2009 Mar;23(3):486-91 [19092854.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Apr;15(4):421-31 [19285629.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jun;58(6):855-65 [18841361.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):427-36 [19225975.001]
  • [Cites] Leukemia. 2009 Apr;23(4):641-8 [19151770.001]
  • [Cites] Transfusion. 2009 Feb;49(2):362-71 [19389215.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jul;58(7):1047-55 [19018534.001]
  • [Cites] Int J Hematol. 2009 May;89(4):460-9 [19360457.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] J Immunother. 2009 May;32(4):408-14 [19342964.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Leuk Res. 2009 Jul;33(7):948-57 [19233469.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1669-77 [19225777.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1679-90 [19283381.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):478-88 [19641204.001]
  • [Cites] Scand J Immunol. 2009 Sep;70(3):194-205 [19703009.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):503-5 [19707241.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1736-45 [19556425.001]
  • [Cites] Cytotherapy. 2009;11(5):653-68 [19530029.001]
  • [Cites] Expert Rev Vaccines. 2009 Oct;8(10):1415-25 [19803762.001]
  • [Cites] Curr Opin Immunol. 2009 Oct;21(5):525-30 [19717293.001]
  • [Cites] Br J Haematol. 2010 Mar;148(6):879-89 [20064159.001]
  • [Cites] Haematologica. 2010 Jul;95(7):1191-7 [20081055.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Cytotherapy. 2006;8(6):554-8 [17148031.001]
  • [Cites] Clin Exp Immunol. 2007 May;148(2):189-98 [17437417.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):186-95 [17593025.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Front Biosci. 2008;13:2022-9 [17981688.001]
  • [Cites] Leuk Res. 2008 Dec;32(12):1842-8 [18614230.001]
  • [Cites] Eur J Haematol. 2008 Oct;81(4):281-8 [18573171.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):372-81 [18205840.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6 [17855129.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):128-34 [17906298.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):407-15 [18058809.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):486-94 [18249062.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3633-43 [10572074.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):709-19 [11378266.001]
  • [Cites] Cancer Immunol Immunother. 2001 Jun;50(4):173-80 [11459169.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3750-6 [11739182.001]
  • [Cites] Clin Exp Immunol. 2001 Dec;126(3):403-11 [11737054.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):383-9 [11839382.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4343-9 [12036860.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2075-82 [12533031.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):442-51 [12580958.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1481-7 [12627513.001]
  • [Cites] Leukemia. 2003 Apr;17(4):716-30 [12682629.001]
  • [Cites] Adv Cancer Res. 2003;90:127-56 [14710949.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Nat Immun Cell Growth Regul. 1983-1984;3(4):165-80 [6597341.001]
  • [Cites] Blood. 1986 Nov;68(5):1030-5 [3768529.001]
  • [Cites] Semin Hematol. 1987 Jan;24(1):40-54 [3547672.001]
  • [Cites] Leuk Res. 1990;14(11-12):967-73 [2280612.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):43-9 [1998596.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):88-99 [2069169.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2158-63 [7919330.001]
  • [Cites] Cell. 1995 Apr 7;81(1):9-12 [7536631.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(9):891-7 [9156262.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):989-99 [9169643.001]
  • [Cites] Leukemia. 1998 Jan;12(1):52-8 [9436920.001]
  • [Cites] Scand J Immunol. 1998 Jan;47(1):54-62 [9467659.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):914-9 [9508173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8639-44 [10411928.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2002-7 [15470487.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1768-73 [16079891.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):152-7 [16611305.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):35-46 [19449004.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):73-9 [19526239.001]
  • [Cites] Curr Gene Ther. 2009 Oct;9(5):396-408 [19860654.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3909-16 [19710498.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2109-17 [19626050.001]
  • [Cites] Haematologica. 2010 Jan;95(1):71-8 [19648166.001]
  • [Cites] J Immunol. 2010 Feb 15;184(4):1885-96 [20089697.001]
  • [Cites] Haematologica. 2010 Mar;95(3):485-93 [19903675.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):451-63 [18261837.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2542-53 [18240144.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):104-9 [18381105.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):889-98 [18494931.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2222-7 [18688847.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):521-41 [18790453.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2924-32 [18790773.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):771-7 [18756547.001]
  • [Cites] Br J Haematol. 2008 Sep;142(6):877-88 [18564358.001]
  • (PMID = 20529084.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 108
  • [Other-IDs] NLM/ PMC2909404
  •  go-up   go-down


2. Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F, Schweiger C, Nuessler V, Schmid C, Kolb HJ, Schmetzer HM: Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand J Immunol; 2005 Jul;62(1):86-98
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
  • Functional dendritic cells (DC) are professional antigen-presenting cells (APC) and can be generated in vitro from healthy as well as from leukaemic cells from acute myeloid leukemia (AML) patients giving rise to APC of leukaemic origin-presenting leukaemic antigens.
  • We describe the generation and characterization of DC from different mononuclear cell (MNC) fractions from 50 AML patients under different serum-free culture conditions, determine the optimal culture conditions and compare the results with that from 23 healthy donors.
  • In parallel cultures, we compared DC harvests after 7- or 14-day culture, with total or adherent MNC or T-cell depleted MNC or peripheral blood (PB) or bone marrow-MNC (BM-MNC), thawn or fresh MNC, in Xvivo or CellGro serum-free media, +/-10% autologous plasma or +/-FL.
  • In detail, we could show that AML-DC harvests were higher after 10-14 days culture (healthy DC: 7 days); total or adherent PB or BM-MNC fractions yield comparable DC counts, however, from magnetic cell sorting (MACS)-depleted MNC fractions or thawn MNC lower DC counts can be generated.
  • Optimal harvest of vital and mature DC from AML samples was obtained with a granulocyte/macrophage-colony stimulating factor, interleukin-4, FL and tumour necrosis factor-alpha-containing serum-free Xvivo medium after 10-14 days of culture (36/26% DC; 38/64% vital DC; 46/51% mature DC were generated from AML/healthy MNC samples).
  • Surface marker profiles (e.g. costimulatory antigen expressing) of DC obtained from AML samples were comparable with that of healthy DC.
  • The leukaemic derivation of AML-DC was demonstrated by the persistence of the clonal cytogenetic aberration in the DC or by coexpression of leukaemic antigens on DC.
  • Autologous T-cell activation of leukaemia-derived DC was demonstrated in cases with AML.
  • We demonstrate that the generation of leukaemia-derived DC is feasable in AML under serum-free culture conditions giving rise to DC with comparable characteristics as healthy DC and offering an anti-leukaemia-directed immunotherapeutical vaccination strategy in AML.
  • [MeSH-major] Bone Marrow Cells / immunology. Cell Culture Techniques. Dendritic Cells / immunology. Leukemia, Myeloid / immunology. Leukocytes, Mononuclear / immunology
  • [MeSH-minor] Acute Disease. Adult. Aged. Antigens, CD / analysis. Culture Media, Serum-Free. Female. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Interleukin-4 / pharmacology. Lymphocyte Activation. Male. Middle Aged. T-Lymphocytes / immunology. Tumor Necrosis Factor-alpha / pharmacology. Vaccination / methods

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091128.001).
  • [ISSN] 0300-9475
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Culture Media, Serum-Free; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


3. Navaratne S, Blakeley CJ, Hashemi K: Superior sagittal sinus thrombosis, an unusual presentation of acute myeloid leukaemia: a case report. Emerg Med J; 2005 Aug;22(8):586-9
Genetic Alliance. consumer health - Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior sagittal sinus thrombosis, an unusual presentation of acute myeloid leukaemia: a case report.
  • [MeSH-major] Leukemia, Myeloid / complications. Sagittal Sinus Thrombosis / etiology
  • [MeSH-minor] Acute Disease. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046766.001).
  • [ISSN] 1472-0213
  • [Journal-full-title] Emergency medicine journal : EMJ
  • [ISO-abbreviation] Emerg Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1726864
  •  go-up   go-down


Advertisement
4. Yang SC, Chuang MH, Li DK: The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemia. Br J Clin Pharmacol; 2010 Feb;69(2):209-11
MedlinePlus Health Information. consumer health - Heart Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemia.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Heart Failure / chemically induced. Idarubicin / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Tachycardia, Ventricular / chemically induced

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1978 Nov;65(5):823-32 [707541.001]
  • [Cites] Expert Opin Pharmacother. 2007 Jun;8(8):1039-58 [17516870.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2827-34 [7595745.001]
  • [Cites] Clin Pharmacol Ther. 1981 Aug;30(2):239-45 [7249508.001]
  • (PMID = 20233187.001).
  • [ISSN] 1365-2125
  • [Journal-full-title] British journal of clinical pharmacology
  • [ISO-abbreviation] Br J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2824485
  •  go-up   go-down


5. Zenz T, Döhner K, Denzel T, Döhner H, Stilgenbauer S, Bullinger L: Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol; 2008 May;141(5):742-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Proto-Oncogene Proteins c-akt / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410456.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / platelet protein P47; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


6. Breuckmann F, Barkhausen J, Erbel R: Cardiac involvement of acute myeloid leukaemia. Heart; 2006 Aug;92(8):1095

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement of acute myeloid leukaemia.
  • [MeSH-major] Heart Neoplasms / diagnosis. Leukemia, Myeloid / diagnosis. Sick Sinus Syndrome / etiology
  • [MeSH-minor] Acute Disease. Adult. Echocardiography. Electrocardiography. Humans. Magnetic Resonance Angiography. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844859.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1861113
  •  go-up   go-down


7. Arruda WO, Montú MB, de Oliveira Mde S, Ramina R: Acute myeloid leukaemia induced by mitoxantrone: case report. Arq Neuropsiquiatr; 2005 Jun;63(2A):327-9
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia induced by mitoxantrone: case report.
  • Promyelocitic leukaemia (type M3) and other forms of acute myeloblastic leukaemias (M4 and M5) have been described in a few MS patients who received MX during their treatment.
  • We describe a white female patient, 47 year-old, with SPMS (EDSS = 4) with 14 years of disease.
  • She received MX during her disease and developed acute promyelocytic leukaemia (M3), with severe thrombocytopenia 30 months later.
  • Other cases of treatment related to AML are reviewed and discussed.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Leukemia, Promyelocytic, Acute / chemically induced. Mitoxantrone / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100984.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


8. Makropoulos V, Alexopoulos EC: Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia? J Occup Med Toxicol; 2006;1:19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia?
  • BACKGROUND: Exposures to high doses of irradiation, to chemotherapy, benzene, petroleum products, paints, embalming fluids, ethylene oxide, herbicides, pesticides, and smoking have been associated with an increased risk of acute myelogenous leukemia (AML).
  • Although there in no epidemiological evidence of relation between X-ray developer, fixer and replenisher liquids and AML, these included glutaraldehyde which has weakly associated with lymphocytic leukemia in rats and hydroquinone has been increasingly implicated in producing leukemia, causing DNA and chromosomal damage, inhibits topo-isomerase II, alter hematopoiesis and inhibit apoptosis of neoplastic cells.
  • In July 2001, woman A, 38-years-old, was diagnosed as having acute monocytic leukaemia (FAB M5).
  • The patient did not respond to therapy and died three weeks later.
  • In August 2001, woman B, 35-year-old, was diagnosed with acute promyelocytic leukaemia (FAB M3).
  • Both women were non smokers without any medical history.
  • They concluded that shielding was inadequate for balcony's door but personal monitoring did not show any exceeding of TLV of 20 mSv yearly and cytogenetics analysis did not reveal findings considered to be characteristics of ionizing exposure.
  • CONCLUSION: The findings support the hypothesis that the specific AML cases might have originated from exposure to chemicals, especially hydroquinone and/or glutaraldehyde.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 1;65(9):3527-30 [15867342.001]
  • [Cites] Toxicol Pathol. 2005;33(4):415-24 [16036858.001]
  • [Cites] Occup Environ Med. 2005 Dec;62(12):861-7 [16299095.001]
  • [Cites] Br J Radiol. 1991 May;64(761):455-60 [2036572.001]
  • [Cites] Toxicol Appl Pharmacol. 1989 Mar 1;97(3):440-53 [2609342.001]
  • [Cites] Australas Radiol. 1986 Aug;30(3):281-6 [3814001.001]
  • [Cites] Ann Occup Hyg. 1993 Jun;37(3):287-95 [8346876.001]
  • [Cites] Br J Ind Med. 1993 Feb;50(2):107-11 [8435342.001]
  • [Cites] Occup Environ Med. 1996 Jul;53(7):450-4 [8704868.001]
  • [Cites] Ann Occup Hyg. 1996 Aug;40(4):423-35 [8806214.001]
  • [Cites] Stem Cells. 1996 Nov;14(6):730-42 [8948030.001]
  • [Cites] Ann Occup Hyg. 1997 Dec;41(6):691-8 [9375527.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):312-20 [9703276.001]
  • [Cites] Mol Pharmacol. 1999 May;55(5):894-901 [10220568.001]
  • [Cites] J Epidemiol. 1999 Apr;9(2):61-72 [10337078.001]
  • [Cites] Crit Rev Toxicol. 1999 May;29(3):283-330 [10379810.001]
  • [Cites] Exp Hematol. 2000 Feb;28(2):169-76 [10706073.001]
  • [Cites] Occup Med (Lond). 2000 Jan;50(1):39-42 [10795391.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):309-18 [11207146.001]
  • [Cites] Leukemia. 2001 Jan;15(1):10-20 [11243376.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Health Phys. 2002 Apr;82(4):455-66 [11906134.001]
  • [Cites] Am J Ind Med. 2003 Feb;43(2):132-41 [12541267.001]
  • [Cites] Occup Environ Med. 2003 Apr;60(4):254-61 [12660373.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3080-9 [12784345.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1296-304 [15129224.001]
  • [Cites] Environ Mol Mutagen. 2004;43(4):258-64 [15141365.001]
  • [Cites] Biochim Biophys Acta. 2004 Sep 6;1690(1):11-21 [15337166.001]
  • [Cites] Chem Res Toxicol. 2005 Apr;18(4):761-70 [15833037.001]
  • (PMID = 16872480.001).
  • [ISSN] 1745-6673
  • [Journal-full-title] Journal of occupational medicine and toxicology (London, England)
  • [ISO-abbreviation] J Occup Med Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1544343
  •  go-up   go-down


9. Poloni A, Capelli D, Trappolini S, Costantini B, Montanari M, Gini G, Scortechini I, Mancini G, Discepoli G, Leoni P, Olivieri A: Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. Br J Haematol; 2010 Jul;150(1):119-21
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377587.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


10. Marks DI: 'Rainy day' stem cell storage for adult patients with acute myeloid leukaemia in first complete remission. Intern Med J; 2008 Aug;38(8):680-1; author reply 681
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'Rainy day' stem cell storage for adult patients with acute myeloid leukaemia in first complete remission.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Specimen Handling / standards. Stem Cells
  • [MeSH-minor] Adult. Humans. Practice Guidelines as Topic. Remission Induction. Stem Cell Transplantation / standards. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Intern Med J. 2008 Apr;38(4):229-34 [18380700.001]
  • [CommentOn] Intern Med J. 2008 Apr;38(4):227-8 [18380699.001]
  • (PMID = 18808569.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Australia
  •  go-up   go-down


11. Sorour Y, Dalley CD, Snowden JA, Cross NC, Reilly JT: Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene. Br J Haematol; 2009 Jul;146(2):225-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene.
  • [MeSH-major] Eosinophilia / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Mutation / genetics. Oncogene Proteins, Fusion / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. mRNA Cleavage and Polyadenylation Factors / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466970.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / mRNA Cleavage and Polyadenylation Factors; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


12. Lim SH, Hulsey M, Esler WV: Resolution of Behcet's disease after non-myeloablative allogeneic stem cell transplant for acute myeloid leukaemia. Rheumatology (Oxford); 2009 Jan;48(1):88-9
MedlinePlus Health Information. consumer health - Behcet's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of Behcet's disease after non-myeloablative allogeneic stem cell transplant for acute myeloid leukaemia.
  • [MeSH-major] Behcet Syndrome / therapy. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987011.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


13. Mahfouz RA, Otrock ZK, Mehawej H, Farhat F: Kodamaea (Pichia) ohmeri fungaemia complicating acute myeloid leukaemia in a patient with haemochromatosis. Pathology; 2008 Jan;40(1):99-101
MedlinePlus Health Information. consumer health - Hemochromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kodamaea (Pichia) ohmeri fungaemia complicating acute myeloid leukaemia in a patient with haemochromatosis.
  • [MeSH-major] Fungemia / complications. Hemochromatosis / complications. Leukemia, Myeloid, Acute / complications. Pichia
  • [MeSH-minor] Adult. Female. Humans. Opportunistic Infections / complications. Opportunistic Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038331.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 12
  •  go-up   go-down


14. Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, Barber L, Mufti GJ, Farzaneh F: Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study. Br J Haematol; 2009 Jun;145(6):749-60
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study.
  • Immunotherapeutic strategies may promote T and/or natural killer (NK) cell cytotoxicity.
  • NK cells have the potential to exert a powerful anti-leukaemia effect, as demonstrated by studies of allogeneic transplantation.
  • We have previously shown that CD80/interleukin 2 (IL2) lentivirus (LV)-transduced AML cells stimulate in-vitro T cell activation.
  • The present study demonstrated that allogeneic and autologous culture of peripheral blood mononuclear cells with CD80/IL2-expressing AML cells also promoted NK cell cytotoxicity.
  • Expression of the activation receptors NKp30, NKp44, CD244, CD25, CD69 and HLA-DR significantly increased following allogeneic culture and a consistent increased expression of NKp30, NKp44, NKp46, NKG2D, NKG2C and CD69, and up-regulation of the cytolytic marker CD107a was detected following autologous culture with LV-CD80/IL2 AML cells.
  • Furthermore, increased NK cell lysis of K562 and primary AML blasts was detected.
  • The lytic activity increased by twofold against K562 (from 46.6% to 90.4%) and allogeneic AML cells (from 11.8% to 20.1%) following in-vitro stimulation by CD80/IL2-expressing AML cells.
  • More importantly for potential therapeutic applications, lysis of primary AML cells by autologous NK cells increased by more than 40-fold (from 0.4% to 22.5%).
  • These studies demonstrated that vaccination of patients with CD80/IL2-transduced AML cells could provide a powerful strategy for T/NK cell-mediated stimulation of anti-leukaemic immunological responses.
  • [MeSH-major] Antigens, CD80 / genetics. Immunotherapy, Adoptive / methods. Interleukin-2 / genetics. Leukemia, Myeloid, Acute / therapy. Natural Killer T-Cells / immunology. Transduction, Genetic / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cytotoxicity, Immunologic. Female. Flow Cytometry. Genetic Vectors / administration & dosage. Genetic Vectors / genetics. Humans. Immunophenotyping. K562 Cells. Lentivirus / genetics. Lymphocyte Activation. Male. Middle Aged. Statistics, Nonparametric. Tumor Cells, Cultured. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388935.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/E005896/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Interleukin-2
  •  go-up   go-down


15. Jerez A, del Mar Osma M, Amigo M, Ortuño FJ: Faggot cells in an HIV-positive patient with inv(16)/therapy-related acute myeloid leukaemia. Br J Haematol; 2010 Sep;150(6):646
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Faggot cells in an HIV-positive patient with inv(16)/therapy-related acute myeloid leukaemia.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16 / genetics. Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary / pathology. Neutrophils / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytoplasmic Granules / pathology. Hodgkin Disease / drug therapy. Humans. Lymphoma, AIDS-Related / drug therapy. Male

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666775.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Schiller GJ, O'Brien SM, Vey N, Pigneux A, DeAngelo DJ, Karp JE, Hudak D, Kell J, Stuart RK, Giles FJ: Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine. J Clin Oncol; 2009 May 20;27(15_suppl):7050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine.
  • : 7050 Background: Treatment of older pts with AML is often complicated by comorbidities and pts with comorbidities are often underrepresented in clinical trials.
  • The HCT-CI, which was developed in pts receiving allogeneic SCT, has been applied to pts receiving induction therapy for AML in an effort to assist in therapeutic and investigational decisions (Kantarjian 2006; Etienne 2007; Giles 2007).
  • HCT-CI scores have been shown to be predictive of early death and survival in pts ≥ 60 years receiving induction therapy for AML, with early death rates of 3%, 11%, and 29% for pts with HCT-CI scores of 0, 1-2, and ≥ 3, respectively (Giles 2007).
  • METHODS: 140 pts age ≥ 60 with poor risk de novo AML from two phase II studies were scored for comorbidity by HCT-CI.
  • CONCLUSIONS: The majority (81%) of these older poor risk AML pts treated with laromustine had a HCT-CI score ≥ 3, confirming the poor risk nature of this patient group.
  • The induction death rate for pts treated with laromustine and with HCT-CI score ≥ 3 was lower than that reported for a group of pts with HCT-CI score ≥ 3 treated with standard induction chemotherapy (14% vs 29%; Giles 2007).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961414.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chamberlain MC, Raizer J: Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J Clin Oncol; 2009 May 20;27(15_suppl):e13030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML).
  • The diagnosis of tMDS was determined by bone marrow biopsy in seven patients.
  • Three patients were diagnosed with AML as well (in two determined by bone marrow and one at autopsy).
  • Interval from last chemotherapy exposure to diagnosis of tMDS/AML ranged from 3 months to 31 months (median 24 months).
  • Five patients have died, two as a consequence of recurrent brain tumor, one as a complication of transplantation, and due due to AML.
  • CONCLUSIONS: Although rare, induction of tMDS/AML following extended use of alkylator-based chemotherapy may become more relevant with the evolving practice to treat gliomas for protracted periods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962878.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chaubey R, Sazawal S, Mahapatra M, Saxena R: Low frequency of RAS and absence of FLT3-ITD gene mutations in patients with Myelodysplastic Syndromes in India: AIIMS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e22231

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22231 Background: Chromosomal abnormalities and molecular detection has potential importance for diagnosis and prognosis of MDS, although the mechanisms underlying the development of MDS and their progressive evolution to AML are still largely unknown.
  • Since, no studies have been reported from India on the prevalence of N-RAS, K- RAS point mutation in codon 12 and FLT3-ITD mutations in patients with MDS, we undertook this study.
  • PCR-RFLP and nested PCR-RFLP were used for the detection of point mutation in codon 12 of N-RAS and K-RAS.
  • One out of 53 patients (2%) was found positive for N-RAS and four patients were positive for K-RAS (8%) mutation.
  • The presence of N-RAS codon 12 mutation was associated with the poor survival.
  • FLT3-ITD mutation was not observed in any of our cases, which is in contrast to 3% reported from the West.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964108.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sierra J, Harms R, Mo M, Vogel CL: Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some authors have suggested that pegfilgrastim-induced bone pain is unpredictable and refractory to analgesics (Kirshner 2007), though that impression may not be uniformly accepted.
  • The incidence of bone pain was determined by treatment (pegfilgrastim, filgrastim, or placebo), chemotherapy (taxane-containing or not), cycle, severity, age, and body surface area (BSA).
  • In studies comparing pegfilgrastim (n=74) and filgrastim (n==7) in pts with AML and NHL, 52% were female, and the mean (SD) age was 50 (15.1) years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Sekeres M, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Berger D: Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS). J Clin Oncol; 2009 May 20;27(15_suppl):7009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five pts experienced serious AEs, and there were 2 cases of disease progression to AML: one pt in the QWSC cohort who received romiplostim for 4 weeks and one in the Q2WSC cohort who received romiplostim for 20 weeks.
  • For pts who completed 8 weeks treatment, 15/23 (65%) achieved a plt response, defined by IWG 2006 criteria, and 14/23 (61%) did not require a plt transfusion during this period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, d'Amore F: Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):8528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8528 Background: Classical Hodgkin lymphoma (cHL) is characterized by a minority of neoplastic cells surrounded by a heterogeneous background of non-neoplastic cells.
  • CD163 expression was assessed immunohistochemically and the degree of intratumoral LAM infiltration was scored semi-quantitatively.
  • All pts were homogeneously treated with either chemo-radiotherapy (localised disease) or ABVD chemotherapy (advanced disease).
  • The histological subtypes were: nodular sclerosis (NS)-type I, 167 cases (59 %); NS-type II, 71 (25%); mixed cellularity (MC), 44 (15 %); lymphocyte-rich, lymphocyte-depleted and cHL-NOS, each one case.
  • Of 253 pts with assessable International Prognostic Score (IPS), 204 had a low-risk (≤ 2) and 49 a high risk (>2) profile.
  • Furthermore, a high expression of CD163 strongly correlated to stage IV disease (p=0.035), presence of B-symptoms (p=0.008), lymphocytopenia (p=0.003), hypersedimentation (p=0.009).
  • CONCLUSIONS: In cHL, a high number of intratumoral CD163+ monocytes/macrophages correlates with adverse outcome and with clinical parameters reflecting underlying aggressive disease biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960903.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 5-yr survivors, the impact of changes in therapy on cause-specific late mortality has not been thoroughly assessed.
  • Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).
  • No significant improvement in late mortality attributable to Non-Recur/Ext causes was seen.
  • Additionally, all-cause mortality was significantly lower in more recent eras for 5-year survivors of ALL, AML, Hodgkin, NHL, and CNS tumors, but not neuroblastoma and Ewing's Sarcoma where an increase in cumulative incidence of late mortality was seen in more recent eras.
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).
  • Importantly, however, efforts to reduce the toxicity of more recent therapies have not produced detectable reduction in mortality attributable to other health conditions including sequelae of cancer therapy (non-Recur/Ext causes of death), which would include death from second malignancy, cardiac and pulmonary conditions.
  • Worsening late mortality for 5-year survivors of neuroblastoma and Ewing's sarcoma may be due to improved use of salvage therapies that delay, but do not ultimately prevent death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Queudeville M, Eckhoff SM, Debatin K, Meyer LH: Correlatoin of apoptosis signaling in primary pediatric BCP-ALL xenograft cells with the kinetics of engraftment in vivo in a NOD/SCID model and patient outcome. J Clin Oncol; 2009 May 20;27(15_suppl):10043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10043 Background: We previously identified the importance of intact apoptosis signaling for treatment response in pediatric ALL and AML by analyzing two key apoptogenic events, caspase-3 activation and cytochrome c release.
  • Using a NOD/SCID mouse model for pediatric BCP-ALL we found that short time from transplant to overt leukemia in the recipient mice (short time to leukemia, TTLshort) determines poor patient outcome.
  • METHODS: In this study we investigated the importance of deficient apoptosis signaling for leukemia engraftment in this model.
  • CONCLUSIONS: Our finding in the NOD/SCID/huALL model matches our results in pediatric ALL and AML to conclude that the functional integrity of a downstream apoptotic checkpoint is an important feature regulating leukemia biology.
  • Thus, deficient apoptosis signaling appears to determine rapid engraftment of leukemia cells in the NOD/SCID model in vivo and consequently poor patient outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962469.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mansberg R, Nicholls M, Chan C, Emmett L, Van der Wall H: Tuberculous epididymo-orchitis presenting as pyrexia of unknown origin during acute myeloid leukaemia consolidation therapy. Intern Med J; 2009 Feb;39(2):137-8
MedlinePlus Health Information. consumer health - Fever.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculous epididymo-orchitis presenting as pyrexia of unknown origin during acute myeloid leukaemia consolidation therapy.
  • [MeSH-major] Epididymitis / diagnosis. Fever / diagnosis. Leukemia, Myeloid, Acute / therapy. Orchitis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356194.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


25. Cascavilla N, D'Arena G, Greco MM, Melillo L, Merla E, Carella AM: Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia. Br J Haematol; 2008 Sep;142(5):852-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin as maintenance therapy after autologous stem cell transplantation in elderly patients with acute myeloid leukaemia.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510691.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


26. Singal A, Pandhi D, Rusia U: Purpuric pityriasis rosea-like eruption: a cutaneous marker of acute myeloid leukaemia. J Eur Acad Dermatol Venereol; 2007 Jul;21(6):822-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purpuric pityriasis rosea-like eruption: a cutaneous marker of acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Pityriasis Rosea / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17567315.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Giannoutsos I, Rosenfeld D: Bone marrow lipofuscin in a patient with acute myeloid leukaemia and extensive marrow necrosis. Br J Haematol; 2007 Jul;138(2):129
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow lipofuscin in a patient with acute myeloid leukaemia and extensive marrow necrosis.
  • [MeSH-major] Bone Marrow / metabolism. Leukemia, Myeloid, Acute / metabolism. Lipofuscin / analysis

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17489981.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lipofuscin
  •  go-up   go-down


28. Galimberti S, Ghio F, Guerrini F, Ciabatti E, Grassi S, Ferreri MI, Petrini M: WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br J Haematol; 2010 May;149(3):451-4
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis. WT1 Proteins / biosynthesis
  • [MeSH-minor] Aged. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085581.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


29. Ferretti G, Papaldo P: Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Breast Cancer Res Treat; 2008 May;109(1):187-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis


30. Balasooriya BL, Fonseka HF, Williams S, Premawardhena A: Oro-genital ulcers with a positive pathergy test in acute myeloid leukaemia. Ceylon Med J; 2009 Dec;54(4):131-2
MedlinePlus Health Information. consumer health - Behcet's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oro-genital ulcers with a positive pathergy test in acute myeloid leukaemia.
  • [MeSH-major] Behcet Syndrome / diagnosis. Genital Diseases, Female / immunology. Leukemia, Myeloid, Acute / immunology. Oral Ulcer / immunology. Ulcer / immunology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Erythema Nodosum / diagnosis. Erythema Nodosum / immunology. Female. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052857.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


31. Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA: Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. Br J Haematol; 2008 Jun;142(2):318-20
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492100.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


32. Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø: Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases. Hematology; 2010 Oct;15(5):338-43
Hazardous Substances Data Bank. VALPROIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
  • Disease-stabilizing therapy with the histone deacetylase inhibitor valproic acid and all-trans retinoic acid (ATRA) has been investigated in acute myelogenous leukemia (AML) in a number of trials.
  • Experimental studies suggest that valproic acid induces a broad chemoresistant phenotype in human AML cells; however, clinical observations combining valproic acid with conventional therapy in a disease-stabilizing setting have not been reported that would confirm this as a clinical issue.
  • Hyperleukocytosis was controlled by low doses of the cytotoxic drugs, no unexpected toxicity appeared and the increases in normal peripheral blood cell counts induced by ATRA+valproic acid+theophylline were maintained during therapy.
  • We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acute Disease. Aged. Aged, 80 and over. Female. Histone Deacetylase Inhibitors / administration & dosage. Humans. Hydroxyurea / administration & dosage. Male. Middle Aged. Treatment Outcome. Valproic Acid / administration & dosage

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20863429.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 614OI1Z5WI / Valproic Acid; E7WED276I5 / 6-Mercaptopurine; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


33. Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM: Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis; 2010 Aug;15(8):946-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).
  • The novel small molecule ingenol 3-angelate (PEP005) has been shown previously to induce apoptosis in leukaemic cell lines and primary AML cells, an effect that requires the expression of protein kinase C-delta (PKCdelta).
  • Here we have investigated signalling events downstream of PKCdelta that determine sensitivity of AML cells to PEP005.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Diterpenes / pharmacology. Leukemia, Myeloid, Acute / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467815.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / 3-ingenyl angelate; 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Enzyme Inhibitors; 0 / Flavonoids; EC 2.7.11.13 / Protein Kinase C-delta; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


34. Yun SJ, Shin MG, Choi C, Kim HJ, Lee JB, Kim SJ, Lee SC, Won YH: Fatal disseminated angioinvasive Fusarium falciforme infection in a patient with acute myeloid leukaemia. Br J Dermatol; 2007 Aug;157(2):407-9
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal disseminated angioinvasive Fusarium falciforme infection in a patient with acute myeloid leukaemia.
  • [MeSH-major] Fusarium / isolation & purification. Leukemia, Myeloid / complications. Mycoses / complications. Opportunistic Infections / complications
  • [MeSH-minor] Acute Disease. Base Sequence. Dermatomycoses / complications. Fatal Outcome. Female. Humans. Middle Aged. RNA, Fungal / genetics. RNA, Ribosomal, 28S / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573871.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Fungal; 0 / RNA, Ribosomal, 28S
  •  go-up   go-down


35. Sibson K, Steward C, Moppett J, Cornish J, Goulden N: Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now? Br J Haematol; 2009 Aug;146(3):342-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Haematol. 2008 Nov;143(4):541-7 [18759760.001]
  • (PMID = 19545292.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


36. Lee CY, Tien HF, Hou HA, Chou WC, Lin LI: Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol; 2008 May;141(5):736-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Marrow / chemistry. Leukemia, Myeloid, Acute / metabolism. Osteopontin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18397342.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


37. Pich A, Godio L: Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7. Leuk Res; 2010 Feb;34(2):e69-70
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory anaemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with chromosomal evolution including monosomy 7.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / pathology. Cell Transformation, Neoplastic. Leukemia, Myeloid, Acute / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744708.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


38. Torres LA, Barbarroja N, Dorado G, Velasco F, López-Pedrera C: VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications. Br J Haematol; 2009 Jun;145(6):836-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / genetics. Membrane Proteins / genetics. Tandem Repeat Sequences. Tyrphostins / therapeutic use. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388942.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Membrane Proteins; 0 / Tyrphostins; 0 / flt3 ligand protein; 146535-11-7 / 6,7-dimethoxy-3-phenylquinoxaline; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


39. Stussi G, Tichelli A, Schanz U, Goede J: Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with RUNX1-RUNX1T1. Br J Haematol; 2009 Aug;146(4):346
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with RUNX1-RUNX1T1.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Hypereosinophilic Syndrome / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388941.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


40. Rodríguez-Romo L, Mancias-Guerra C, González-Llano O, Jaime-Pérez JC, Martínez-Cabriales S, García-Rodríguez F, Gómez-Almaguer D: Outpatient reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia in children. Br J Haematol; 2010 Oct;151(2):200-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia in children.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738308.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


41. Hoeller S, Bihl MP, Arber C, Dirnhofer S, Tzankov A: GATA1 mutations are not a hallmark of acute myeloid leukaemia with t(8;21). J Clin Pathol; 2010 May;63(5):471-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GATA1 mutations are not a hallmark of acute myeloid leukaemia with t(8;21).
  • [MeSH-major] GATA1 Transcription Factor / genetics. Leukemia, Myeloid, Acute / genetics. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418238.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  •  go-up   go-down


42. Hsiao PF, Liu HC, Wu YH: An infant with juvenile xanthogranuloma, multiple café-au-lait macules, acute myeloid leukaemia: an incomplete, rare form of triple association? J Eur Acad Dermatol Venereol; 2008 Nov;22(11):1378-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An infant with juvenile xanthogranuloma, multiple café-au-lait macules, acute myeloid leukaemia: an incomplete, rare form of triple association?
  • [MeSH-major] Cafe-au-Lait Spots / complications. Leukemia, Myeloid, Acute / complications. Xanthogranuloma, Juvenile / complications


43. Guerrini F, Galimberti S, Ciabatti E, Brizzi S, Testi R, Pollastrini A, Falini B, Petrini M: Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. Leukemia; 2007 Sep;21(9):2056-8
MedlinePlus Health Information. consumer health - Genetic Testing.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia.
  • [MeSH-major] Genetic Testing / methods. Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / genetics. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554388.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


44. Martelli MP, Manes N, Liso A, Pettirossi V, Verducci Galletti B, Bigerna B, Pucciarini A, De Marco MF, Pallotta MT, Bolli N, Sborgia M, di Raimondo F, Fabbiano F, Meloni G, Specchia G, Martelli MF, Falini B: A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia. Leukemia; 2008 Dec;22(12):2285-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia.
  • [MeSH-major] Blotting, Western / methods. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Nuclear Proteins / genetics. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563173.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


45. Villela L, Anders V, Bolaños-Meade J: Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome. Anticancer Drugs; 2010 Apr;21(4):469
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Lymphocyte Transfusion. Myelodysplastic Syndromes / complications. Salvage Therapy


46. Falini B: Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin? Leukemia; 2008 May;22(5):891-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478020.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Editorial; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  • [Number-of-references] 16
  •  go-up   go-down


47. Carmichael CL, Wilkins EJ, Bengtsson H, Horwitz MS, Speed TP, Vincent PC, Young G, Hahn CN, Escher R, Scott HS: Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes. Br J Haematol; 2010 Aug;150(3):382-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Neoplasm Proteins / genetics
  • [MeSH-minor] Base Sequence. Female. Genes, Neoplasm. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Prognosis


48. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E: Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol; 2007 Aug;138(4):555-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy


49. Dawson MA, Whitehead S: Mature neutrophils with multiple Auer rods: a rarity in normal karyotype acute myeloid leukaemia. Br J Haematol; 2007 Apr;137(2):86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature neutrophils with multiple Auer rods: a rarity in normal karyotype acute myeloid leukaemia.
  • [MeSH-major] Inclusion Bodies / pathology. Leukemia, Myeloid / pathology. Neutrophils / pathology
  • [MeSH-minor] Acute Disease. Female. Humans. Karyotyping. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391487.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Mills KI, Walsh V, Gilkes AF, Agrawal SG, Knapper S: Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient. Br J Haematol; 2006 Jan;132(1):116-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / genetics. Mutation. Neoplasm Proteins / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2006 Mar;132(5):663. Knapperb, S [corrected to Kanpper, S]
  • (PMID = 16371029.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


51. Hayashi M, Kondoh K, Nakata Y, Kinoshita A, Mori T, Takahashi T, Sakamoto MI, Yamada T: Establishment of a novel childhood acute myeloid leukaemia cell line, KOPM-88, containing partial tandem duplication of the MLL gene and an in vivo model for childhood acute myeloid leukaemia using NOD/SCID mice. Br J Haematol; 2007 May;137(3):221-32
Cellosaurus - a cell line knowledge resource. culture/stock collections - KOPM-88 (CVCL_M647) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a novel childhood acute myeloid leukaemia cell line, KOPM-88, containing partial tandem duplication of the MLL gene and an in vivo model for childhood acute myeloid leukaemia using NOD/SCID mice.
  • MLL gene rearrangement is common in both adult and childhood acute myeloid leukaemia (AML), and its role in oncogenesis has been investigated.
  • We have established a novel cell line containing MLL-PTD derived from an 11-year-old patient with AML and designated as KOPM-88.
  • KOPM-88 cells exhibited certain characteristics associated with the myeloid lineage including abundant primary granules in the cytoplasm and the expression of myeloperoxidase.
  • The cell growth of KOPM-88 was cytokine independent but was accelerated by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.
  • Furthermore, non-obese diabetic/severe combined immunodeficient mice inoculated with KOPM-88 cells exhibited leukaemic infiltrations in the bone marrow and hemiparalysis because of compression myelopathy.
  • This is the first report of an in vivo animal model exhibiting the systemic involvement of childhood AML containing MLL-PTD.
  • KOPM-88 cells and our murine model may be useful for investigating the pathogenesis of childhood AML associated with MLL gene rearrangement.
  • [MeSH-major] Gene Duplication. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Tandem Repeat Sequences / genetics
  • [MeSH-minor] Animals. Antigens, Surface / immunology. Cell Division / immunology. Cell Line, Tumor. Cell Transplantation / methods. Child. Cytokines / immunology. Disease Models, Animal. Fatal Outcome. Flow Cytometry / methods. Gene Rearrangement / genetics. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence / methods. Male. Mice. Mice, Inbred NOD. Mice, SCID. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408461.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Cytokines; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


52. Tsujimura H, Mimura N, Ise M, Sakai C, Shimada H, Nagata M, Kumagai K: Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer.
  • METHODS: From July 2000 to March 2008, 348 patients with esophageal squamous cell carcinoma underwent CRT.
  • RESULTS: Four patients, who achieved CR after CRT, developed leukemia.
  • Case1, 60-yo-male, developed overt acute myeloid leukemia (AML) from myelodysplastic syndrome 48 months after CRT.
  • Case2, 64-yo-male, developed AML M0 with t(9;22)(q34;q11) 44 months after CRT.
  • Case3, 72-yo-male, developed Burkitt leukemia with t(8;14)(q24;q32) 19 months after CRT.
  • Case4, 65-yo-male, developed myeloid crisis of chronic myelogenous leukemia with complicated abnormalities including t(9;22)(q34;q11) 48 months after CRT.
  • Case 1 and 3 had localized disease and received single course of neoadjuvant CRT.
  • Case 2 and 4 had advance disease and received 2 courses of CRT.
  • All patients eventually died of leukemia.
  • To this end, atypical cytogenetic abnormalities seen in the present cases give a new insight into the biology of therapy-related leukemia.
  • Notably, this is the first report presenting the incidence of secondary leukemia by nedaplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Anagnostopoulos C, Jadwat Y, Wood NH, Meyerov R, Lemmer J, Bouckaert M, Feller L: A report of oral extramedullary acute myeloid leukaemia (AML) in an 8-year-old girl with newly diagnosed AML-M4Eo. SADJ; 2007 Oct;62(9):390, 392-3
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A report of oral extramedullary acute myeloid leukaemia (AML) in an 8-year-old girl with newly diagnosed AML-M4Eo.
  • Acute myeloid leukaemia (AML), characterized by proliferation of immature neoplastic myeloid cells, is uncommon in childhood.
  • We present a case of an 8-year-old girl with AML-M4Eo who had an extramedullary leukaemic tumour in the oral cavity.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Bone Marrow Neoplasms / pathology. Child. Diagnosis, Differential. Eosinophilia / pathology. Fatal Outcome. Female. Humans. Immunophenotyping / methods. Sepsis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260548.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


54. Santos FP, Qiao W, Cortes JE, Jones D, Ravandi F, Verma D, Kantarjian H, Borthakur G: Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML).
  • : 7015 Background: Mutations of the FLT3 gene (in special internal tandem duplication -ITD) are common in normal karyotype AML (NK-AML) and are associated with shorter relapse free and overall survival (OS).
  • METHODS: The records of patients (pts) with newly diagnosed AML (from 2003 to 2007) were reviewed.
  • A Cox model was fit for OS, and non-significant variables were eliminated in a step-down fashion with a p- value cut-off of p = .10.
  • No difference was found in median OS between FLT3-mutated and FLT3- wild type pts in the good risk group (not reached (NR) vs NR, P = 0.57) nor in the poor risk group (55 vs 24 weeks, P = 0.44).
  • In intermediate risk, OS was worse in FLT3-ITD positive pts (33 vs 89 weeks, P < 0.0001) but not in FLT3-TKD positive pts (77 vs 70 weeks, P = 0.89).
  • CONCLUSIONS: In our cohort of pts, FLT3 mutations did not have a prognostic impact in AML with good and poor risk karyotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961388.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Fenton C, Perry CM: Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia. BioDrugs; 2006;20(2):137-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia.
  • Gemtuzumab ozogamicin (Mylotarg) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalization, releases a derivative of the cytotoxic calicheamicin component.
  • In the US, it is approved as monotherapy in patients aged>or=60 years with a first relapse of AML who are ineligible for other cytotoxic therapy.
  • Monotherapy with gemtuzumab ozogamicin results in complete remission (CR) or CR with incomplete platelet recovery (CRp) in approximate, equals 25% of adults (including those aged>or=60 years) with CD33-positive AML in first relapse.
  • Preliminary data indicate a potential role for gemtuzumab ozogamicin as a component of induction or consolidation regimens in adults and, based on an early study, in the treatment of children with AML, although randomized, controlled studies are needed.
  • Gemtuzumab ozogamicin is a valuable new treatment option for patients aged>or=60 years with CD33-positive AML in first relapse for whom other cytotoxic chemotherapy is not considered appropriate; patients with a first CR (CR1) of >12 months are likely to have the best outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Drugs. 2005;65(16):2405-27 [16266206.001]
  • (PMID = 16626170.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


56. Verdeguer A: Genetic alterations in children and adolescents with acute myeloid leukaemia. Clin Transl Oncol; 2010 Sep;12(9):590-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations in children and adolescents with acute myeloid leukaemia.
  • Acute Myeloid Leukemia is a clinically and genetically heterogeneous disease, in which cytogenetic aberrations are the most important factors to determine biological behavior and prognosis.
  • More than 20 different chromosomal abnormalities have been identified in a high percentage of children (70-85%) with the novo AML.
  • Differences according to the age of patients and mainly in relation to adult population have been enhanced, although the low incidence of AML in children and the high number of abnormalities make difficult to accurately define the prognosis significance of these aberrations.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20851799.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Pinquart M, Höffken K, Silbereisen RK, Wedding U: Social support and survival in patients with acute myeloid leukaemia. Support Care Cancer; 2007 Jan;15(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Social support and survival in patients with acute myeloid leukaemia.
  • GOAL OF WORK: The purpose of the study was to assess the effect of the reported availability of social support on the 2-year survival of patients with acute myelogenous leukaemia (AML).
  • MATERIALS AND METHODS: Fifty patients with newly diagnosed AML were asked to rate the level of available social support after diagnosis was made, but before the start of chemotherapy.
  • CONCLUSIONS: For patients with AML, the availability of social support is relevant for decreased mortality, after accounting for age, functional impairment, dosage of chemotherapy and cytogenetic risk group.
  • [MeSH-major] Adaptation, Psychological. Leukemia, Myeloid / psychology. Social Support
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Surveys and Questionnaires. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004090.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


58. Zhuravleva J, Paggetti J, Martin L, Hammann A, Solary E, Bastie JN, Delva L: MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol; 2008 Nov;143(3):378-82
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish.
  • The inv(8)(p11q13) chromosomal abnormality, described in acute myeloid leukaemias (AML), fuses the histone acetyl-transferase (HAT) MYST3 (MOZ) gene with another HAT gene, NCOA2 (TIF2).
  • An AML developed in 2 of 180 MYST3/NCOA2-EGFP-expressing embryos, 14 and 26 months after injection of the fusion gene in a one-cell embryo, respectively.
  • This leukaemia was characterised by an extensive invasion of kidneys by myeloid blast cells.
  • This model, which is the first zebrafish model of AML, demonstrates the oncogenic potency of MYST3/NCOA2 fusion gene.
  • [MeSH-major] Histone Acetyltransferases / genetics. Leukemia, Myeloid, Acute / genetics. Nuclear Receptor Coactivator 2 / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Animals. Animals, Genetically Modified. Disease Models, Animal. Gene Fusion. Kidney / pathology. Microinjections / methods. Reverse Transcriptase Polymerase Chain Reaction / methods. Zebrafish / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18729850.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NCOA2 protein, human; 0 / Nuclear Receptor Coactivator 2; 0 / Oncogene Proteins, Fusion; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


59. Shankar S, Rytina E, Burrows NP: Acute myeloid leukaemia presenting with eczema. Clin Exp Dermatol; 2006 Jul;31(4):593-4
MedlinePlus Health Information. consumer health - Eczema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukaemia presenting with eczema.
  • [MeSH-major] Eczema / etiology. Leukemia, Myeloid / complications
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Female. Humans

  • Genetic Alliance. consumer health - Eczema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16716173.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


60. Tansley S, Gibbons S: Capecitabine-induced acute myeloid leukaemia. N Z Med J; 2009 May 8;122(1294):118-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine-induced acute myeloid leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Leukemia, Myeloid, Acute / chemically induced

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465957.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C, German Acute Myeloid Leukaemia Cooperative Group, Study Alliance Leukemia Investigators: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet; 2010 Dec 11;376(9757):2000-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
  • BACKGROUND: About 50% of patients (age ≥60 years) who have acute myeloid leukaemia and are otherwise medically healthy (ie, able to undergo intensive chemotherapy) achieve a complete remission (CR) after intensive chemotherapy, but with a substantially increased risk of early death (ED) compared with younger patients.
  • METHODS: Multivariate regression analysis was used to develop risk scores with or without knowledge of the cytogenetic and molecular risk profiles for a cohort of 1406 patients (aged ≥60 years) with acute myeloid leukaemia, but otherwise medically healthy, who were treated with two courses of intensive induction chemotherapy (tioguanine, standard-dose cytarabine, and daunorubicin followed by high-dose cytarabine and mitoxantrone; or with high-dose cytarabine and mitoxantrone in the first and second induction courses) in the German Acute Myeloid Leukaemia Cooperative Group 1999 study.
  • Risk prediction was validated in an independent cohort of 801 patients (aged >60 years) with acute myeloid leukaemia who were given two courses of cytarabine and daunorubicin in the Acute Myeloid Leukaemia 1996 study.
  • FINDINGS: Body temperature, age, de-novo leukaemia versus leukaemia secondary to cytotoxic treatment or an antecedent haematological disease, haemoglobin, platelet count, fibrinogen, and serum concentration of lactate dehydrogenase were significantly associated with CR or ED.
  • INTERPRETATION: The scores for acute myeloid leukaemia can be used to predict the probability of CR and the risk of ED in older patients with acute myeloid leukaemia, but otherwise medically healthy, for whom intensive induction chemotherapy is planned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Internet. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1967-8 [21131041.001]
  • (PMID = 21131036.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  • [Investigator] Fuss H; Hennesser D; Potenberg J; Ludwig WD; Schöndube D; Späth-Schwalbe E; Hesse-Amojo S; Mayr A; Grüneisen A; Boewer C; Derwahl M; Englisch HJ; Rick O; Siegert W; Notter M; Uharek L; Thiel E; Dörken B; Arnold R; Huhn D; Knigge O; Kolloch R; Krümpelmann U; Weh AJ; Zumsprekel A; Teschendorf C; Stechstor M; Trenn G; Wörmann B; Pflüger KH; Wolff T; Hertenstein B; Thomssen H; Peyn A; Rasche H; Heidtmann HH; Marquard F; Hähnel M; Fiedler F; Herbst R; Hallek M; Staib P; Heike M; Niederste-Hollenberg A; Pielken H; Hindahl H; Röllig C; Schaich M; Thiede C; Kramer M; Ehninger G; Aul C; Giagounidis A; Lange W; Kuhlemann SE; Flasshove M; Karow J; Gramatzki M; Helm G; Fuchs R; Schlegel F; Saal JG; Serve H; Kiehl M; Höffkes HG; Arland M; Meckenstock G; Giagounidis A; Haase D; Trümper L; Griesinger F; Gropp C; Depenbusch R; Eimermacher H; Schütte W; Haak U; Fasshaür E; Schmitz N; Stuhlmann R; Braumann D; Schmidt H; Buhrmann K; Balleisen L; Schubert J; Dürk H; Burk M; Ho AD; Mahlknecht U; Lange JG; Schmitz-Hübner U; Bartholomäus A; Fauser A; Link H; Hagmann FG; Wolf M; Ritter B; Frieling T; Planker M; Köchling G; Hartmann F; Middeke H; Gründgens C; Constantin C; Schalk KP; Jost KA; Fetscher S; Schmielau J; Wagner T; Uppenkamp M; Hoffmann M; Hehlmann R; Lengfelder E; Neubauer A; Schwonzen M; Spangenberg H; Bodenstein H; Tischler J; Graeven D; Kohl D; Heuer T; Pohlmann H; Brack N; Nibler K; Fleckenstein D; Haferlach T; Haferlach C; Schnittger S; Kern W; Emmerich B; Dengler R; Schlag B; Hiddemann W; Braess J; Spiekermann K; Berdel WE; Büchner T; Kienast J; Mesters R; Müller-Tidow C; Krug U; Koschmieder S; Volpert S; Wieacker P; Sauerland MC; Heinecke A; Köpcke W; Wilhelm M; Wandt H; Schäfer-Eckart K; Hirsch F; Seeber B; Hartlapp J; Hegge T; Peceny R; Koch O; Innig G; Südhoff T; Wagner T; Maschmeyer G; Kreuser ED; Schenk M; Reichle A; Andreesen R; Huff H; Schönberger D; Geer T; Heissmeyer H; Labenz J; Gassmann W; Gaske T; Käsberger J; Aulitzky WE; Leimer L; Clemens MR; Mahlberg R; Frickhofen N; Fuhr HG; Schwerdtfeger R; Augener W; Engberding R; Winter R; Sandmann M; Einsele H; Weissinger F; Rückle-Lanz H; Brugger W; Papakonstantinou G; Kreibich U; Schott G; Sommer S; Zschille W
  •  go-up   go-down


62. Negosanti L, Aceti A, Bianchi T, Corvaglia L, Negosanti F, Sgarzani R, Morselli PG, Cipriani R, Negosanti M, Patrizi A, Faldella G: Adapting a Vacuum Assisted Closure dressing to challenging wounds: negative pressure treatment for perineal necrotizing fasciitis with rectal prolapse in a newborn affected by acute myeloid leukaemia. Eur J Dermatol; 2010 Jul-Aug;20(4):501-3
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adapting a Vacuum Assisted Closure dressing to challenging wounds: negative pressure treatment for perineal necrotizing fasciitis with rectal prolapse in a newborn affected by acute myeloid leukaemia.
  • We report the case of a newborn with acute myeloid leukaemia, who developed perineal necrotizing fasciitis due to Pseudomonas Aeruginosa, after twenty days of life.
  • [MeSH-major] Fasciitis, Necrotizing / therapy. Leukemia, Myeloid, Acute / complications. Negative-Pressure Wound Therapy / methods. Perineum. Pseudomonas Infections / therapy. Rectal Prolapse / therapy

  • Genetic Alliance. consumer health - Necrotizing fasciitis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406723.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


63. Lucena-Araujo AR, Panepucci RA, dos Santos GA, Jácomo RH, Santana-Lemos BA, Lima AS, Garcia AB, Araújo AG, Falcão RP, Rego EM: The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. Br J Haematol; 2008 Jul;142(1):74-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
  • We compared TATP73 and DeltaNTP73 expression in acute myeloid leukaemia (AML) samples and normal CD34(+) progenitors.
  • Amongst AML blasts, TATP73 was more expressed in AML harbouring the recurrent genetic abnormalities (RGA): PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11, whereas higher DeltaNTP73 expression was detected in non-RGA cases.
  • TP53 expression did not vary according to DeltaNTP73/TATP73 expression ratio.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. DNA-Binding Proteins / genetics. Genes, p53 / genetics. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422993.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 04079A1RDZ / Cytarabine
  •  go-up   go-down


64. Ravandi Kashani F, Cortes J, Faderl S, Jones D, Byrd A, Brandt M, Garcia-Manero G, Levis M, Andreeff M, Kantarjian H: Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).
  • It selectively induces apoptosis in FLT3-mutant human AML cell lines at nM concentrations.
  • METHODS: Objectives of this study are to determine the tolerability and efficacy of combination of S with chemotherapy.
  • In the phase I part, pts with relapsed AML were treated with escalating doses of S (400 mg qod, 400 mg daily, 400 mg bid) for 7 days during induction, and 400 mg bid was established as safe.
  • RESULTS: 10 pts (median age 34, range 21-58) with relapsed AML (median prior therapy 2, range 1-6) were treated in the phase I .
  • 5 pts have relapsed; median CR duration has not been reached, (range; 0.2+ - 10.6+ mo).
  • CONCLUSIONS: S can be safely combined with IA; it has a high CR rate in frontline therapy of younger pts with AML, in particular those with FLT3 mutations.
  • Correlative studies confirm potent activity of S against FLT3 signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Fanci R, Pecile P, Di Lollo S, Dini C, Bosi A: Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report. Mycoses; 2008 Jul;51(4):354-6
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report.
  • Here we describe a rare case of pulmonary mucormycosis and simultaneous cervical lymphadenitis in a patient with acute myeloid leukaemia.
  • The diagnosis of Mucor is very difficult, especially in severely immunocompromised patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / microbiology. Lymphadenitis / microbiology. Mucormycosis / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855847.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


66. Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H: Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis; 2007 Nov;26(11):843-5
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia.
  • A neutropenic patient with acute myeloid leukaemia experienced a breakthrough infection of Trichosporon asahii during posaconazole treatment.
  • [MeSH-major] Cross Infection / microbiology. Leukemia, Myeloid, Acute / complications. Mycoses / microbiology. Triazoles / therapeutic use. Trichosporon / drug effects. Trichosporon / isolation & purification

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690928.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 6TK1G07BHZ / posaconazole; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  •  go-up   go-down


67. Arcese W, Buccisano F, Cerretti R, Picardi A, Rome Transplant Network: Cord blood transplantation in adults with acute myeloid leukaemia. Best Pract Res Clin Haematol; 2010 Jun;23(2):197-206
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cord blood transplantation in adults with acute myeloid leukaemia.
  • Allogeneic haematopoietic stem cell transplantation represents a potential life-saving procedure for many patients affected by acute myeloid leukaemia.
  • However, in the past its application has been limited by the availability of a HLA matched sibling.
  • To date, an allogeneic transplant from alternative haematopoietic stem cell sources (volunteer unrelated donor, umbilical cord blood, haploidentical family donor) should be considered for all patients with high-risk disease defined by integration of clinical and biological prognosticators.
  • Furthermore, the decreased risk of GVHD, the use of reduced intensity conditionings and the graft of double cord blood units permit to extend cord blood transplant to a higher proportion of adult patients with acute myeloid leukaemia, which is predominantly diagnosed in the elderly age.
  • A multicentric, prospective intention-to-treat study is warranted in order to define which haematopoietic stem cell source represents the best choice for allogeneic transplant in high-risk acute myeloid leukaemia.
  • [MeSH-major] Blood Donors. Cord Blood Stem Cell Transplantation / methods. Histocompatibility. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Age Factors. Female. Graft vs Host Disease / prevention & control. Histocompatibility Testing / methods. Humans. Male. Multicenter Studies as Topic. Risk Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20837331.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Jabbour E, Faderl S, Ravandi F, Konopleva M, Verstovsek S, Cortes J, Wierda W, Newsome WM, Yang H, Kantarjian H, Garcia-Manero G: Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).
  • : 7004 Background: Standard induction therapy for pts with AML has not changed over the last 2 decades nor has the outcome of these pts.
  • We designed a phase II study of V with IA as front-line therapy for MDS/AML.
  • METHODS: Pts with untreated int-2/high-risk MDS or AML ages 15-65 with adequate liver and renal functions and PS, and EF ≥ 50% were eligible.
  • 3 pts with relapsed/refractory AML were treated in the run-in phase.
  • 8 (47%) had secondary disease.
  • The median PFS has not been reached.
  • CONCLUSIONS: The combination of IA and V is safe and active in AML/MDS.
  • Results will be compared with those of a parallel IA study at MDACC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kunivayalil S, Jain A, Satheesh C, Tejinder S, Lakshmaiah K, Suresh TM, Lokanatha D, Babu G: A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia.
  • It can be used during induction and consolidation chemotherapy in acute myeloid leukemia (AML).
  • Few studies addressed the use of pegylated filgrasim in AML.
  • Safety profile and complete remission status did not differ between the two groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964003.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Green C, Linch DC, Gale RE: Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome. Br J Haematol; 2008 Jul;142(3):423-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.
  • FLT3 internal tandem duplication mutant levels >50%, indicative of bi-allelic disease in some cells, are associated with a particularly poor prognosis in acute myeloid leukaemia; lower levels have an intermediate prognosis relative to wild-type FLT3.
  • To examine whether a small population of homozygous mutant cells is responsible for the worse relapse risk rather than heterozygous disease per se, we determined the genetic composition of 34 intermediate mutant level (25-50%) samples.
  • Bi-allelic disease in intermediate mutant level cases is uncommon and heterozygous disease is sufficient for adverse outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537976.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


71. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol; 2007 Feb;136(4):624-7
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
  • The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation.
  • HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy.
  • The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Severity of Illness Index
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223919.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


72. Rosenberg C, Finger PT, Furlan L, Iacob CE: Bilateral epibulbar granulocytic sarcomas: a case of an 8-year-old girl with acute myeloid leukaemia. Graefes Arch Clin Exp Ophthalmol; 2007 Jan;245(1):170-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral epibulbar granulocytic sarcomas: a case of an 8-year-old girl with acute myeloid leukaemia.
  • PURPOSE: An 8-year-old girl with a history of acute myeloid leukaemia (AML) presented with bilateral ocular discomfort, conjunctival injection, photophobia, and epiphora.
  • RESULTS: Granulocytic sarcomas were suspected and leukaemic infiltration was confirmed by fine-needle aspiration biopsy based cytopathologic examination.
  • CONCLUSIONS: Epibulbar granulocytic sarcoma in AML is rare (particularly in a child).
  • We describe the first high-frequency ultrasound images and illustrate the use of a minimally invasive fine-needle aspiration biopsy technique to confirm our diagnosis.
  • [MeSH-major] Conjunctiva / pathology. Leukemia, Myeloid, Acute / pathology. Leukemic Infiltration. Sarcoma, Myeloid / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642360.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


73. Chevallier P, Hunault-Berger M, Larosa F, Dauriac C, Garand R, Harousseau JL: A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leuk Res; 2009 Aug;33(8):1124-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.
  • This was a phase II investigation of high-dose imatinib in 15 adult patients with relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia (AML).
  • Imatinib 600 mg daily was administered for 1 month followed by dose escalation to 800 mg daily for a maximum of 2 months.
  • No clinical responses were reported with early death due to disease progression reported in 7 patients.
  • While no activity was seen in this phase II trial, the findings of the study do not rule out efficacy in subsets of AML with imatinib-sensitive Kit mutations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Genes, abl. Leukemia, Myeloid, Acute / drug therapy. Piperazines / administration & dosage. Proto-Oncogene Proteins c-kit. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Aged. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990444.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


74. Pedranzini L, Mottadelli F, Ronzoni S, Rossella F, Ferracin M, Magnani I, Roversi G, Colapietro P, Negrini M, Pelicci PG, Larizza L: Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment. Leuk Res; 2010 Oct;34(10):1287-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment.
  • The t(8;21) Acute Myeloid Leukaemia (AML) Kasumi-1 cell line with N822K KIT mutation, is a model system for leukemogenesis.
  • As AML initiating cells reside in the CD34(+)CD38(-) fraction, we addressed the refined cytogenomic characterization and miRNA expression of Kasumi-1 cell line and its FACS-sorted subpopulations focussing on this compartment.
  • [MeSH-major] Antigens, CD34 / analysis. Antigens, CD38 / analysis. Leukemia, Myeloid, Acute / genetics. MicroRNAs / analysis
  • [MeSH-minor] Cell Line, Tumor. Chromosomes, Human, Pair 4. Comparative Genomic Hybridization. Gene Expression Profiling. Humans. Immunophenotyping. Proto-Oncogene Proteins c-kit / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20227111.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / MicroRNAs; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


75. Sato M, Kako S, Oshima K, Sato K, Terasako K, Kimura S, Nakasone H, Okuda S, Yamazaki R, Higuchi T, Nishida J, Kanda Y: Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing chemotherapy for acute myeloid leukaemia. Scand J Infect Dis; 2010;42(2):97-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing chemotherapy for acute myeloid leukaemia.
  • We retrospectively evaluated the serum high-sensitivity C-reactive protein (CRP) level before chemotherapy for the prediction of infectious events during neutropenia in patients with acute myeloid leukaemia.
  • A receiver-operating characteristic (ROC) curve revealed that the serum CRP level just before the first consolidation chemotherapy, but not just before the induction chemotherapy, had a significant predictive value for febrile neutropenia (FN) at a cut-off value of 0.19 mg/dl and documented infection (DI) at a cut-off value of 0.26 mg/dl.
  • [MeSH-major] C-Reactive Protein / analysis. Drug Therapy. Forecasting / methods. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Opportunistic Infections / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082574.001).
  • [ISSN] 1651-1980
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


76. Morris KL, Adams JA, Liu Yin JA: Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Leuk Res; 2009 Aug;33(8):1096-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
  • We have investigated the effect of cloretazine (VNP40101M or Laromustine), a novel sulfonylhydrazine alkylating agent with significant antileukaemic activity, alone, or combined with cytarabine or daunorubicin, on the proliferation, viability and apoptosis of cell lines and acute myeloid leukaemia blast cells in vitro.
  • Cloretazine alone induced a concentration-dependent inhibition of proliferation, reduction in cell viability and an increase in apoptosis in all samples tested.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Cell Proliferation / drug effects. Hydrazines / pharmacology. Leukemia, Myeloid, Acute / drug therapy. Sulfonamides / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cytarabine / pharmacology. Daunorubicin / pharmacology. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor / methods. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 Aug;33(8):1022-3 [19328547.001]
  • (PMID = 19268363.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Sulfonamides; 04079A1RDZ / Cytarabine; 14J2G0U3NQ / laromustine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


77. Baldus CD, Mrózek K, Marcucci G, Bloomfield CD: Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol; 2007 Jun;137(5):387-400
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
  • Normal cytogenetics are detected pretreatment in approximately 45% of patients with de novo acute myeloid leukaemia (AML); thus this constitutes the single largest cytogenetic group of AML.
  • Here we critically review the molecular heterogeneity among AML patients with normal cytogenetics and discuss how these data may translate into a prognostic, molecular-based treatment stratification that may improve the currently unsatisfactory outcome of these patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Proto-Oncogene Proteins / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488484.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 101140; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / CA 77658
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins
  • [Number-of-references] 92
  •  go-up   go-down


78. Steensma D, Kantarjian H, Wijermans P: Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS). J Clin Oncol; 2009 May 20;27(15_suppl):7011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data from each clinical trial supporting overall improvement, duration of improvement, time to AML or death, progression-free survival (PFS), and transfusion independence was assessed.
  • RESULTS: Patients had IPSS classification scores of intermediate-2 or high-risk (D-0007, 70%; EORTC-06011, 93%; ID03-0180, 66%; DACO-020, 46%) and de novo MDS (D-0007, 87%; EORTC-06011, 88%; ID03-0180, 70%; DACO-020, 89%).
  • Comparable overall improvement (complete response [CR] + partial response [PR] + hematologic improvement [HI]), time to AML or death, and PFS was observed across all trials (Table).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Boyd EM, Bench AJ, Vaghela KJ, Campbell GN, Chowdhury FB, Gudgin EJ, Scott MA, Erber WN: Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes. Leukemia; 2009 Jun;23(6):1164-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myeloid leukaemia with t(8;16)(p11;p13);MOZ-CBP and polymorphisms in detoxifying and DNA repair genes.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics. Polymorphism, Genetic. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158836.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MOZ-CBP fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


80. Basecke J, Whelan JT, Griesinger F, Bertrand FE: The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol; 2006 Nov;135(4):438-49

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MLL partial tandem duplication in acute myeloid leukaemia.
  • Mixed lineage leukaemia gene-partial tandem duplications (MLL-PTD) characterise acute myeloid leukaemia (AML) with trisomy 11 and AML with a normal karyotype.
  • MLL-PTD confer a worse prognosis with shortened overall and event free survival in childhood and adult AML.
  • In spite of these clinical observations, the leukaemogenic mechanism has, so far, not been determined.
  • This review summarises clinical studies on MLL-PTD positive AML and recent experimental findings on the putative leukaemogenic role of MLL-PTD.
  • [MeSH-major] Gene Duplication. Leukemia, Myeloid / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Tandem Repeat Sequences
  • [MeSH-minor] Acute Disease. Cell Transformation, Neoplastic / genetics. Chromosomes, Human, Pair 11 / genetics. DNA, Neoplasm / genetics. Genetic Predisposition to Disease. Histone-Lysine N-Methyltransferase. Humans. Prognosis. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965385.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 81
  •  go-up   go-down


81. Langabeer SE, Owen CJ, McCarron SL, Fitzgibbon J, Smith OP, O'Marcaigh A, Browne P: A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. Eur J Haematol; 2010 Dec;85(6):552-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Thrombocytopenia / genetics
  • [MeSH-minor] Female. Humans. Male. Pedigree. Propensity Score. Sex Factors. Stem Cell Transplantation. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722699.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


82. Berneman ZN, Anguille S, Van Marck V, Schroyens WA, Van Tendeloo VF: Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis. Br J Haematol; 2010 Apr;149(1):152-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Polyethylene Glycols / therapeutic use. Primary Myelofibrosis / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Humans. Male. Middle Aged. Recombinant Proteins. Remission Induction

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19995392.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


83. Smith LL, Pearce D, Smith ML, Jenner M, Lister TA, Bonnet D, Goff L, Fitzgibbon J: Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia. Br J Haematol; 2006 Apr;133(1):103-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. DNA Mutational Analysis. Leukemia, Myeloid / genetics. Neoplasm, Residual / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Acute Disease. Base Sequence. Humans. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512836.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha
  •  go-up   go-down


84. Willems L, Suarez F, Baubion N, Decaudin D, Ghez D, Hermine O, Varet B, Rubio MT: High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancer. Ann Oncol; 2009 Mar;20(3):597-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174451.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


85. Bow EJ, Meddings JB: Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia; 2006 Dec;20(12):2087-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia.
  • Intestinal barrier function was prospectively examined in the course of a clinical trial evaluating the efficacy and safety of lisofylline for reducing cytotoxic therapy-induced intestinal epithelial damage-related infectious morbidity in patients receiving standard remission-induction therapy for acute myeloid leukaemia.
  • The absorption and permeation of oral D-Xylose, lactulose and mannitol were measured weekly from baseline until marrow recovery in adult recipients of idarubicin plus cytarabine for untreated acute myeloid leukaemia.
  • These studies were correlated with non-haematologic chemotherapy-related toxicities reflecting mucosal damage, including nausea, vomiting, stomatitis, diarrhoea, abdominal pain and systemic infection.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Infection / etiology. Intestinal Mucosa / drug effects. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082779.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; A1TA934AKO / Xylose
  •  go-up   go-down


86. Barber LM, Barlow RA, Meyer S, White DJ, Will AM, Eden TO, Taylor GM: Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia. Br J Haematol; 2005 Sep;130(5):796-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited FANCD1/BRCA2 exon 7 splice mutations associated with acute myeloid leukaemia in Fanconi anaemia D1 are not found in sporadic childhood leukaemia.
  • [MeSH-major] Alternative Splicing. Fanconi Anemia / genetics. Genes, BRCA2. Leukemia, Myeloid / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Disease Susceptibility. Exons. Fanconi Anemia Complementation Group D2 Protein. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2006 May;133(4):446-8; author reply 448 [16643458.001]
  • [ErratumIn] Br J Haematol. 2005 Dec;131(5):672
  • (PMID = 16115142.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FANCD2 protein, human; 0 / Fanconi Anemia Complementation Group D2 Protein; 0 / Nuclear Proteins
  •  go-up   go-down


87. McLornan DP, McMullin MF, Johnston P, Longley DB: Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin Drug Metab Toxicol; 2007 Jun;3(3):363-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms of drug resistance in acute myeloid leukaemia.
  • Resistance to chemotherapy in acute myeloid leukaemia is a major obstacle to a successful outcome for many patients.
  • This article reviews the factors that determine leukaemic cell chemosensitivity and discusses the potential for rationally guided therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, Myeloid / drug therapy. Models, Biological
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Caspases / metabolism. Enzyme Activation / drug effects. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539744.001).
  • [ISSN] 1742-5255
  • [Journal-full-title] Expert opinion on drug metabolism & toxicology
  • [ISO-abbreviation] Expert Opin Drug Metab Toxicol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600452
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.4.22.- / Caspases
  • [Number-of-references] 138
  •  go-up   go-down


88. McLintock LA, Gibson BE, Jones BL: Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia. Br J Haematol; 2005 Mar;128(6):737
MedlinePlus Health Information. consumer health - Aspergillosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed pulmonary fungal infection with Aspergillus fumigatus and Absidia corymbifera in a patient with relapsed acute myeloid leukaemia.
  • [MeSH-major] Absidia. Aspergillosis / complications. Aspergillus fumigatus. Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / complications. Mucormycosis / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755275.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


89. Rhee CK, Rhee JH, Kim HJ, Choi SM, Kim YJ, Kim DW, Lee JW, Min WS, Shin WS, Kim CC, Ahn KJ: T-cell lymphoproliferative disorder following a full haplotype-mismatched haematopoietic stem cell transplant in a patient with acute myeloid leukaemia. Bone Marrow Transplant; 2005 Sep;36(5):461-3
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoproliferative disorder following a full haplotype-mismatched haematopoietic stem cell transplant in a patient with acute myeloid leukaemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Living Donors. T-Lymphocytes

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968275.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


90. Juncà J, Moreno M, Mate JL, Milla F: [Concomitant diagnosis of acute myeloid leukaemia and chronic lymphoproliferative disorder with AA amyloidosis as a final event]. Med Clin (Barc); 2010 Jun 19;135(3):136-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant diagnosis of acute myeloid leukaemia and chronic lymphoproliferative disorder with AA amyloidosis as a final event].
  • [Transliterated title] Diagnóstico simultáneo de una leucemia aguda mieloide y un síndrome linfoproliferativo crónico, con amiloidosis AA como episodio final.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoproliferative Disorders / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Amyloidosis AA.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766258.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Serum Amyloid A Protein
  •  go-up   go-down


91. Gunawardana DH, Grigg A: Use of 18F-fluorodeoxyglucose positron emission tomography to change management and assess response to therapy in post-transplant extramedullary relapse of acute myeloid leukaemia. Intern Med J; 2010 Jun;40(6):466-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of 18F-fluorodeoxyglucose positron emission tomography to change management and assess response to therapy in post-transplant extramedullary relapse of acute myeloid leukaemia.
  • [MeSH-major] Fluorodeoxyglucose F18. Leukemia, Myeloid, Acute / radionuclide imaging. Leukemia, Myeloid, Acute / surgery. Positron-Emission Tomography / methods. Postoperative Complications / radionuclide imaging. Stem Cell Transplantation
  • [MeSH-minor] Adult. Disease Management. Humans. Male. Middle Aged. Secondary Prevention. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20636832.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Guinn BA, Bullinger L, Thomas NS, Mills KI, Greiner J: SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. Br J Haematol; 2008 Jan;140(2):250-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Neoplasm Proteins / blood. Repressor Proteins / blood. Spindle Apparatus / genetics. Translocation, Genetic
  • [MeSH-minor] Cell Cycle / genetics. Humans

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028484.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Repressor Proteins; 164289-47-8 / synovial sarcoma X breakpoint proteins
  •  go-up   go-down


93. Lo WT, Cheng SN, Wang CC, Chu ML: Extensive necrotising fasciitis caused by Pseudomonas aeruginosa in a child with acute myeloid leukaemia: case report and literature review. Eur J Pediatr; 2005 Feb;164(2):113-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive necrotising fasciitis caused by Pseudomonas aeruginosa in a child with acute myeloid leukaemia: case report and literature review.
  • [MeSH-major] Fasciitis, Necrotizing / microbiology. Fasciitis, Necrotizing / therapy. Leukemia, Myeloid / complications. Pseudomonas Infections / complications. Pseudomonas aeruginosa / isolation & purification
  • [MeSH-minor] Acute Disease. Adolescent. Anti-Bacterial Agents / therapeutic use. Debridement. Face. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemorrhage / microbiology. Hemorrhage / therapy. Humans. Male. Parenteral Nutrition, Total

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490233.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


94. Vitthala S, Misra PK: Fertility after B-Lynch suture in a patient previously treated for acute myeloid leukaemia. Eur J Obstet Gynecol Reprod Biol; 2008 Jan;136(1):133-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility after B-Lynch suture in a patient previously treated for acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid, Acute. Postpartum Hemorrhage / surgery. Suture Techniques. Uterus / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141397.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Ireland
  •  go-up   go-down


95. Schalk E, Neum S, Kranz S, Scheinpflug K, Mohren M: Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib. Leuk Res; 2009 Mar;33(3):e6-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Philadelphia Chromosome. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466968.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


96. Trikalinos NA, Soupir CP, Dey BR: Lineage switch of acute lymphocyctic leukaemia with t(4;11)(q21;q23) into acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation. Br J Haematol; 2009 Apr;145(2):262-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch of acute lymphocyctic leukaemia with t(4;11)(q21;q23) into acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Disease Progression. Female. Humans

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208102.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


97. Marbello L, Ricci F, Nosari AM, Turrini M, Nador G, Nichelatti M, Tedeschi A, Vismara E, Morra E: Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res; 2008 Aug;32(8):1221-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature.
  • Hyperleukocytic acute myeloid leukaemia is considered to have a poor prognosis due to high early death rate secondary to leukostasis.
  • Supportive treatments do not seem to have reduced early exitus in this subset of patients.
  • Clinical characteristics and outcome of 45 consecutive adult patients with newly diagnosed acute myeloid leukaemia presenting to our institution with a white cell count (WBC) above 100 x 10(9)L(-1) were reviewed.
  • Hyperleukocytosis also significantly reduces the overall survival (OS) but does not significantly influence the disease-free survival (DFS).
  • In most of the reviewed series hyperleukocytosis does not seem to influence the outcome of patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukocytosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313749.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 30
  •  go-up   go-down


98. Stasi R: Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther; 2008 Apr;8(4):527-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
  • BACKGROUND: Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody.
  • OBJECTIVES: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia.
  • RESULTS/CONCLUSIONS: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia.
  • The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation.
  • Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352855.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  • [Number-of-references] 78
  •  go-up   go-down


99. Rollinson S, Smith AG, Allan JM, Adamson PJ, Scott K, Skibola CF, Smith MT, Morgan GJ: RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leuk Res; 2007 Feb;31(2):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia.
  • To investigate whether inherited variants in genes encoding proteins that repair DSBs by HR modulate acute myeloid leukaemia (AML) risk, we have examined the frequency of two variants in the 5' untranslated region (UTR) of RAD51 (RAD51 135 G>C and the RAD51 172 G>T) in a large case-control study of acute myeloid leukaemia (AML).
  • Inheritance of a RAD51 135 C allele was associated with a reduced risk of estimate for AML (odds ratio (OR) 0.56, 95% confidence intervals (CI), 0.38-0.83), while the RAD51 172 T allele was not associated with AML.
  • These data suggest that variants in the RAD51 HR gene may modulate genetic predisposition to AML.
  • [MeSH-major] DNA Repair. Leukemia, Myeloid / genetics. Rad51 Recombinase / genetics. Recombination, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Haplotypes. Humans. Male. Middle Aged. Polymorphism, Genetic / genetics. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890287.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES01896
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.- / RAD51 protein, human; EC 2.7.7.- / Rad51 Recombinase
  •  go-up   go-down


100. Cheung AM, Chow HC, Liang R, Leung AY: A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia. Br J Haematol; 2009 Feb;144(4):484-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia.
  • To examine the differences between primitive bone marrow (BM) and peripheral blood (PB) myeloblasts in acute myeloid leukaemia (AML), we compared CD34(+) myeloblasts of paired BM and PB samples from 14 AML patients in terms of surface phenotype, homing and engraftment in a xenogeneic transplantation model, and gene expression, based on microarray studies and quantitative polymerase chain reaction.
  • Significant correlation between homing and engraftment in AML samples was also noted.
  • In addition, gene expression profiling of CD34(+) cells from five paired BM and PB leukaemic samples showed that genes involved in G-protein and prostaglandin signalling, chemotaxis and stress response, cell proliferation and apoptosis were down-regulated in PB CD34(+) myeloblasts.
  • These data suggested that circulating primitive myeloblasts in AML are functionally different from those residing in the marrow compartment, and such differences may be partly regulated by the BM microenvironment.
  • [MeSH-major] Antigens, CD34 / analysis. Bone Marrow Cells / physiology. Granulocyte Precursor Cells / physiology. Leukemia, Myeloid, Acute / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055666.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Neoplasm
  •  go-up   go-down






Advertisement